CytomX Therapeutics, Inc.
As of Oct 22, 2026, CytomX Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 18, 2026). It closed at $2.44, 63.9% below its 52-week high and below its 200-day average, which is falling.
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is CTMX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CTMX among Biotechnology288th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …288 | CTMX | Stage 4 · wk 5 | 32 | −12.2% |
CytomX Therapeutics: quick answers
What stage is CytomX Therapeutics in?
As of Oct 22, 2026, CytomX Therapeutics (CTMX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 18, 2026 and is in week 5. What the four stages mean
Is CytomX Therapeutics in an uptrend?
No. CytomX Therapeutics is in a Stage 4 downtrend. It trades 38.0% below its 200-day average, which is falling.
How far is CytomX Therapeutics from its 52-week high?
CytomX Therapeutics closed at $2.44 on Oct 22, 2026, 63.9% below its 52-week high of $6.75. Its 52-week low is $2.23.
How has CytomX Therapeutics performed over the past year?
As of Oct 22, 2026, CytomX Therapeutics is down 32.5% over the past year and down 42.6% so far in 2026.
Which sector and industry is CytomX Therapeutics in?
CytomX Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.